B. W. King

发表

Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.

Michelle C. Schaeffer, Carol A. Capriotti, P. A. Harris, 2017, Journal of medicinal chemistry.

Synthesis of the C1-C13 fragment of leucascandrolide A.

B. W. King, M. Crimmins, C. A. Carroll, 2000, Organic letters.

Asymmetric Aldol Additions with Titanium Enolates of Acyloxazolidinethiones: Dependence of Selectivity on Amine Base and Lewis Acid Stoichiometry

B. W. King, M. Crimmins, E. Tabet, 1997 .

Asymmetric aldol additions: use of titanium tetrachloride and (-)-sparteine for the soft enolization of N-acyl oxazolidinones, oxazolidinethiones, and thiazolidinethiones.

B. W. King, M. Crimmins, E. Tabet, 2001, The Journal of organic chemistry.

Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.

Philip Hardwicke, John Bertin, Bryan W King, 2015, Bioorganic & medicinal chemistry.

Synthesis and structure–activity relationship of a novel, non-hydroxamate series of TNF-α converting enzyme inhibitors

A. Tebben, B. W. King, M. Covington, 2007 .

Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[ d]thiazol-5-ylamino)-6-( tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases.

J. Bertin, K. Erhard, M. Convery, 2019, Journal of medicinal chemistry.

Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase.

Michelle C. Schaeffer, Carol A. Capriotti, Paul E. Lamoureux, 2019, Journal of medicinal chemistry.

Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

Peter A. Jones, Philip J. Chapman, P. Grandi, 2021, Nature Cancer.

Asymmetric Total Synthesis of Callystatin A: Asymmetric Aldol Additions with Titanium Enolates of Acyloxazolidinethiones

B. W. King, M. Crimmins, 1998 .

Synthesis and intramolecular photocycloadditions of 2-acyloxy-3-hexenoyl cyclohexenones: Diastereoselectivity in the intramolecular [2+2] photocycloadditions of alkenes and cyclohexenones tethered by four atoms

B. W. King, M. Crimmins, L. E. Guise, 1997 .

An Efficient Asymmetric Approach to Carbocyclic Nucleosides: Asymmetric Synthesis of 1592U89, a Potent Inhibitor of HIV Reverse Transcriptase.

B. W. King, M. Crimmins, 1996, The Journal of organic chemistry.

Asymmetric aldol additions: use of titanium tetrachloride and (-)-sparteine for the soft enolization of N-acyl oxazolidinones, oxazolidinethiones, and thiazolidinethiones.

B. W. King, M. Crimmins, E. Tabet, 2001, The Journal of organic chemistry.

Conversion of potent MMP inhibitors into selective TACE inhibitors.

Bryan W King, B. W. King, M. Covington, 2006, Bioorganic & medicinal chemistry letters.

Synthesis and Intramolecular Photocycloadditions of 2-Acyloxy-3-hexenoyl Cyclohexenones: Diastereoselectivity in the Intramolecular [2 + 2] Photocycloadditions of Alkenes and Cyclohexenones Tethered by Four Atoms.

B. W. King, M. Crimmins, L. E. Guise, 2010 .

DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors.

Deepak Bandyopadhyay, Lauren Dare, Michelle C. Schaeffer, 2016, Journal of medicinal chemistry.

Synthesis and structure–activity relationship of a novel, achiral series of TNF-α converting enzyme inhibitors

J. Trzăskos, T. Maduskuie, B. W. King, 2004 .

RIP3 induces apoptosis independent of pronecrotic kinase activity.

Kenta Moriwaki, Viera Kasparcova, John Bertin, 2014, Molecular cell.

Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases.

J. Bertin, K. Erhard, D. Lipshutz, 2019 .

The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase.

Carol A. Capriotti, J. Bertin, M. Convery, 2016, Journal of medicinal chemistry.

Understanding the origins of time-dependent inhibition by polypeptide deformylase inhibitors.

S. Thrall, C. Duraiswami, T. Meek, 2011, Biochemistry.

Regioselectivity in the palladium-catalyzed addition of carbon nucleophiles to carbocyclic derivatives.

B. W. King, M. Crimmins, P. DeShong, 2002, The Journal of organic chemistry.

Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening

Gang Yao, Bing Xia, Jing Chai, 2017, Nature Communications.

Structural characterization of dicyanopyridine containing DNMT1-selective, non-nucleoside inhibitors.

Xiaodong Cheng, Xing Zhang, M. Pappalardi, 2022, Structure.

An efficient, general asymmetric synthesis of carbocyclic nucleosides: application of an asymmetric aldol/ring-closing metathesis strategy.

W. Zuercher, B. W. King, M. Crimmins, 2000, The Journal of organic chemistry.

An Efficient, General Asymmetric Synthesis of Carbocyclic Nucleosides: Application of an Asymmetric Aldol/Ring‐Closing Metathesis Strategy.

W. Zuercher, B. W. King, M. Crimmins, 2001 .

Abstract 2994: Discovery of selective, noncovalent small molecule inhibitors of DNMT1 as an alternative to traditional DNA hypomethylating agents

J. Briand, R. Prinjha, Mark Cockerill, 2018, Molecular and Cellular Biology / Genetics.

Characterization of GSK′963: a structurally distinct, potent and selective inhibitor of RIP1 kinase

Michelle C. Schaeffer, Carol A. Capriotti, J. Bertin, 2015, Cell Death Discovery.

Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening

Robert H Bates, G. Besra, J. Lelièvre, 2017, Nature Communications.

Structural characterization of dicyanopyridine containing DNMT1-selective, non-nucleoside inhibitors.

Xiaodong Cheng, Xing Zhang, M. Pappalardi, 2022, Structure.